Anxiety Disorders in Elderly Patients

Total Page:16

File Type:pdf, Size:1020Kb

Anxiety Disorders in Elderly Patients J Am Board Fam Pract: first published as 10.3122/jabfm.10.4.280 on 1 July 1997. Downloaded from CLINICAL REVIEW Anxiety Disorders in Elderly Patients Deborah A. Banazak, DO Background: Late-life anxiety disorders, commonly seen in primary care settings, can coexist with other medical and psychiatric illnesses. A variety of effective treatment options is available for these patients. lI-lethods: l\IEDLINE was searched for articles published from 1970 to 1996 using the key words "anxiety," "elderly," "aged," "geriatric," "panic," "obsessive-compulsive," "phobia," and "generalized anxiety disorder." Studies of patients older than 65 years were reviewed. Results: Generalized anxiety disorder, phobias, panic disorder, and obsessive-compulsive disorder are the most common late-life anxiety problems seen by primary care physicians. Patients with these disorders complain of diffuse multisystem symptoms, motor restlessness, and such physiologic symptoms as tachycardia or tachypnea. Comorbid illnesses include depression, alcoholism, drug use, and multisystem disease. Behavioral strategies to address anxiety include an open discussion of the issue, an anxiety diary, psychosocial support, and cognitive-behavioral techniques. Pharmacologic strategies include carefully monitored benzodiazepine, buspirone, or antidepressant therapy. Conclusions: Clinical trials of all anxiety interventions are needed for elderly primary care patients to clarify further whether findings from mixed-age population studies are generalizable to the elderly. (J Am Board Fam Pract 1997;10:280-9.) Caring for an anxious elderly patient can be a medical causes and treatments for anxiety. Finally, challenge for the primary care physician. The dis­ treatment literature (including all case report and tress experienced by such patients can overwhelm double-blind study data) was reviewed to summa­ already strained families, caregivers, and commu­ rize nonpharmacologic and pharmacologic anxi­ nity support systems. Accurately diagnosing the ety treatment interventions. source of the anxiety and providing appropriate, http://www.jabfm.org/ effective treatment are critical for quality of life Epidemiologic Studies and health maintenance. Prevalence Anxiety in elderly patients is a state of hyperalert­ Methods ness in which excessive autonomic arousal results MEDLINE was searched for articles published in diminished patient coping strategies. Anxiety from 1970 to 1996 using the key words "anxiety," becomes manifest in both subjective and objective on 30 September 2021 by guest. Protected copyright. "elderly," "aged," "geriatric," "panic," "obsessive­ ways. Subjectively patients might describe uneasi­ compulsive," "phobia," and "generalized anxiety ness, worry, fear, or unrealistic apprehension. On disorder." Studies of patients older than 65 years the other hand, patients might also complain of were reviewed. Additional studies were selected somatic symptoms and be unaware they are anx­ from article references. Epidemiologic literature ious. Objective symptoms to monitor include was studied using clinical and diagnostic cate­ sweating, muscle tension, tachycardia, facial gri­ gories according to the Diagnostic and Statistical macing, restlessness, and pacing. Manual ofMental Disorders: DSM-I0 A survey of Ten to 20 percent of older patients experience the medical literature provided a summary of clinically important symptoms of anxiety.2 In an elderly community-dwelling population of the Duke Epidemiologic Catchment Area, Blazer Submitted, revised, 13 March 1997. et all found that the 6-month incidence for all From the Department of Psychiatry, Michigan State Univer­ anxiety disorders was 19.7 percent. In Flint's syn­ sity, East Lansing. Address reprint requests to Deborah A. Ba­ 4 nazak, DO, Department of Psychiatry, Michigan State Univer­ thesis of eight surveys consisting of community­ sity, B-109 West Fee Hall, East Lansing, MI 48824-1316. dwelling elders, the following ranges in preva- 280 JADFP July-August 1997 Vol. 10 No.4 J Am Board Fam Pract: first published as 10.3122/jabfm.10.4.280 on 1 July 1997. Downloaded from lence emerged: all anxiety disorders, 0.7 to 18.6 Table 1. Psychiatric Sources of Anxiety. percent; phobic disorder, 0.7 to 10 percent; gen­ Disorder Symptolll SUllllllary eralized anxiety disorder, 0.7 to 7.1 percent; ob­ sessive-compulsive disorder, 0.1 to 0.6 percent; Adjustment disorder Anxiety caused by a recent stressor and panic disorder, 0 percent. In community­ with anxiety based studies generalized anxiety disorder and Generalized anxiety Diffuse constant anxiety and disorder worry phobias are the most common forms of anxiety in Obsessive-compulsive Intmsive thoughts and repetitive elders, although agoraphobia and obsessive-com­ disorder behaviors pulsive disorder might occasionally occur de novo Panie disorder Episodic overwhelming anxiety and in late life.4 autonomic signs These low rates are deceiving because of psy­ Phobias Agoraphobia Fear of being trapped in a place chiatric comorbidity. When elderly patients have from which escape might be symptoms of depression, 33 percent also have difficult and anxiety might occur considerable comorbid anxiety.s In an elderly co­ Social phobia Fear of social embarrassment hort, Ben-Arie and colleagues6 found a high cor­ Specific phobia Fear of specific object or situation relation between panic disorder and depression. Posttraumatic stress Traumatic event reexperienced, disorder creating anxiety Treatment for these patients' conditions con­ sisted largely of benzodiazepine therapy, which neglected their depression and its contribution to fears and worries, such as the fear of robbery, anxiety symptomatology. falls, or strangers, phobias are considered irra­ Determining the source of anxiety can be a tional fears of a specific object or situation. If a clinical challenge. In late life anxiety can be pre­ worry becomes so incapacitating that it causes ir­ cipitated by losses-such as loss of health, mobil­ rational avoidance behaviors and high levels of ity, financial status, lifelong partners, and support distress, it may be considered a phobia. In pri­ systems-and fears of losses. Brief anxiety reac­ mary care settings, up to 7 percent of patients tions that do not impair ongoing coping abil­ older than 65 years can have phobias.s ities should be considered normal. Nervousness The new onset of panic disorder in late life is that consistently impairs the senior's life and rare.4 Panic disorder is most often a preexisting becomes functionally overwhelming, however, is condition associated with other medical or psychi­ pathologic. atric conditions. Raj et al9 studied an elderly com­ http://www.jabfm.org/ Some authors categorize anxiety as primary munity-dwelling population and found that and secondary,7 in which primary anxiety results patients with panic disorder also had chronic pul­ from psychiatrjc conditions, and secondary anxi­ monary disease, vertigo, and Parkinson disease. ety has a medical cause. In the Diagnostic and Sta­ They also found high rates of depression (40 to 52 tistical Manual ofMental Disorders: DSfvl-IV, 1 sec­ percent) in these patients. In mixed-age primary ondary anxiety has been relabeled as anxiety care settings, KatonlO found that 6 percent of pri­ on 30 September 2021 by guest. Protected copyright. disorder caused by a general medical condition. mary care patients exp~rienced panic disorder. Distinguishing between psychiatric and medical Generalized anxiety disorder is common in late causes is especially-difficult in the older patient, as life and accounts for up to 50 percent of all anxi­ comorbid medical and psychiatric conditions al­ ety in this population.4 In primary care settings, most always exist. generalized anxiety occurs in up to 10 percent of patients older than 65 years.s Because this anxiety Psychiatric Sources ofAnXiety is often unrelenting, caring for such patients can Table 1 summarizes the DSM-IV anxiety disor­ challenge the family and physician. Instructing a der categories with disorder-specific symptom patient not to worry is fruitless and can frustrate clusters for each diagnosis. Generally, these clus­ all involved. ters include physiologic symptoms, intense inter­ Obsessive-compulsive disorder is a lifelong dis­ nal discomfort, situationally focused fears, or re­ order that rarely starts in old age. 3 In the elderly current obsessive worries with anxiety-relieving population obsessive-compulsive disorder is more repetitive behaviors. The degree of anxiety varies common among institutionalized women than in with each disorder. While elders can have realistic other community-based populations.4 Obsessions Anxiety Disorders in Elders 281 J Am Board Fam Pract: first published as 10.3122/jabfm.10.4.280 on 1 July 1997. Downloaded from Table 2. Medical Conditions Associated With Anxiety. when the condition began and whether such episodes are recurrent can help determine the System Medical Condition cause. As most primary anxiety disorders have Cardiovascular Angina their origins earlier in life, a history of recurrent Arrhythmia episodes would suggest to the clinician a primary Myocardial infarction anxiety disorder. Clarifying how the illness came Endocrine Diabetes mellitus IIypercalcemia about and in what order symptoms occurred can Hyperthyroidism' help. A medical illness that might have caused IIypocalcemia IIypothyroidism physical signs and symptoms before anxiety be­ Pheochromocytoma came a problem can lead the physician to suspect Gastrointestinal
Recommended publications
  • Fast Facts About Social Phobia
    PLEASE TEAR OUT AND PHOTOCOPY FOR YOUR PATIENTS!! PATIENTS AS PARTNERS Brought to you by The South African Depression and Anxiety Group Tel: +27 11 783 1474 Fax: +27 11 884 7074 E-mail: [email protected] website: www.anxiety.org.za Fast facts about social phobia • Social Phobia affects an estimated one in ten people. It affects people of all races and social classes. • It is estimated that fewer than 25% of people with Social Phobia receive adequate treatment. • The onset of Social Phobia is typically during adolescence, but it may occur in childhood, prior to the age of ten. Approximately 40% of social phobias appear before the age of ten, and 95% before the age of twenty. • Social Phobia is characterised by an underlying fear of scrutiny by people in social situations. It is also associated with fear of performance situations in which embarrassment may occur. • Social Phobia is not shyness. A person with social phobia who finds it unbearable to sign a cheque in public, might be quite extroverted in other contexts. • People with social phobia will avoid social or occupational situations where their particular anxiety might be provoked for eg urinating in a public restroom, or giving a speech. • Common fears include: being introduced to others, meeting people in authority, using the telephone, eating in restaurants or writing in front of others. • When faced with a feared situation, people may have symptoms of panic, e.g. heart palpitations, trembling, sweating, hot and cold flushes and blushing. • 45% of people with social phobia will develop agoraphobia, where their fear of having a panic attack in a social setting will lead them to avoiding social settings altogether.
    [Show full text]
  • Panic Disorder
    Panic Disorder The Anxiety Disorders Association of America (ADAA) is a national 501 (c)3 nonprofit organization whose My heart’s pounding, mission is to promote the prevention, treatment and cure of anxiety disorders and to improve the lives of all it’s hard to breathe. people who suffer from them. Help ADAA help others. Donate now at www.adaa.org. “I feel like I’m going to go crazy or die. For information visit www.adaa.org or contact I have to get out Anxiety Disorders Association of America 8730 Georgia Ave., Ste. 600 of here NOW. Silver Spring, MD 20910 Phone: 240-485-1001 ” Anxiety Disorders Association of America What is Panic Disorder? About Anxiety Disorders We’ve all experienced that gut-wrenching fear when suddenly faced with a threatening or dangerous situation. Crossing the street as a car shoots out of nowhere, losing a child in Anxiety is a normal part of living. It’s the body’s way of telling the playground or hearing someone scream fire in a crowded us something isn’t right. It keeps us from harm’s way and theater. The momentary panic sends chills down our spines, prepares us to act quickly in the face of danger. However, for causes our hearts to beat wildly, our stomachs to knot and some people, anxiety is persistent, irrational and overwhelming. our minds to fill with terror. When the danger passes, so do It may get in the way of day-to-day activities and even make the symptoms. We’re relieved that the dreaded terror didn’t them impossible.
    [Show full text]
  • (Orion) 5 Mg Tablets Buspirone (Orion) 10 Mg Tablets
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME Buspirone (Orion) 5 mg tablets Buspirone (Orion) 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg buspirone hydrochloride. Each tablet contains 10 mg buspirone hydrochloride. Excipient with known effect: 5 mg tablet: Each tablet contains 59.5 mg lactose (as monohydrate) 10 mg tablet: Each tablet contains 118.9 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. 5 mg tablet: White or almost white, oval tablets debossed with ‘ORN 30’ on one side and a score on the other side. The tablet can be divided into equal doses. 10 mg tablet: White or almost white, oval tablets debossed with ‘ORN 31’ on one side and a score on the other side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Buspirone hydrochloride is indicated for the management of anxiety with or without accompanying depression in adults. Buspirone hydrochloride is indicated for the management of anxiety disorders or the short- term relief of symptoms of anxiety with or without accompanying depression. 4.2 Posology and method of administration The usual starting dose is 5 mg given three times daily. This may be titrated according to the needs of the patient and the daily dose increased by 5 mg increments every two or three days depending upon the therapeutic response to a maximum daily dose of 60 mg. After dosage titration the usual daily dose will be 20 to 30 mg per day in divided doses.
    [Show full text]
  • MODERN INDICATIONS for the USE of OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J
    Psychiatria Danubina, 2015; Vol. 27, Suppl. 1, pp 435–437 Conference paper © Medicinska naklada - Zagreb, Croatia MODERN INDICATIONS FOR THE USE OF OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J. Cubała4, Mariusz S. Wiglusz4, Katarzyna Jakuszkowiak-Wojten4, Marek Krzystanek5 & Irena Krupka-Matuszczyk1 1Department of Psychiatry and Psychotherapy, Medical University of Silesia, Katowice, Poland 2“Dialogue” Therapy Centre, Warsaw, Poland 3Department of Pneumonology, Medical University of Silesia, Katowice, Poland 4Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland 5Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland SUMMARY Opipramol is considered as a pharmacological agent that does not fit the classification taking into account the division of antidepressants, antipsychotics and anxiolytics. It has a structure related to tricyclic antidepressants but it has a different mechanism of action, i.e. binding to sigma1 and to sigma2 sites. It has been regarded as an effective drug in general anxiety disorders together with other agents like SSRI`s, SNRI`s, buspirone and pregabalin for many years. It can however also be indicated in other conditions, e.g. it may be used as a premedication in the evening prior to surgery, positive results are also observed in psychopharmacological treatment with opipramol in somatoform disorders, symptoms of depression can be significantly reduced in the climacteric syndrome. The latest data from literature present also certain dangers and side effects, which may result due to opipramol administration. Mania may be induced not only in bipolar patients treated with opipramol, but it can be an adverse drug reaction in generalized anxiety disorder. This analysis shows however that opipramol is an important drug still very useful in different clinical conditions.
    [Show full text]
  • 52Nd Annual Meeting
    ACNP 52nd Annual Meeting Final Program December 8-12, 2013 The Westin Diplomat Resort & Spa Hollywood, Florida President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D. This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology. Dear ACNP Members and Guests, It is a distinct pleasure to welcome you to the 2014 meeting of the American College of Neuropsychopharmacology! This 52nd annual meeting will again provide opportunities for the exercise of the College’s core values: the spirit of Collegiality, promoting in each other the best in science, training and service; participation in Community, pursuing together the goals of understanding the neurobiology of brain diseases and eliminating their burden on individuals and our society; and engaging in Celebration, taking the time to recognize and enjoy the contributions and accomplishments of our members and guests. Under the excellent leadership of Randy Blakely and Pat Levitt, the Program Committee has done a superb job in assembling an outstanding slate of scientific presentations. Based on membership feedback, the meeting schedule has been designed with the goals of achieving an optimal mix of topics and types of sessions, increasing the diversity of participating scientists and creating more time for informal interactions. The presentations will highlight both the breadth of the investigative interests of ACNP membership
    [Show full text]
  • Inappropriate Elimination Disorders
    INAPPROPRIATE ELIMINATION DISORDERS What is “inappropriate elimination”? This is a term that means that a cat is urinating and/or defecating in the house but not in the litter box. What causes it? After medical causes of these problems have been ruled out, the source of the problem is considered a behavioral disorder. Behavioral causes of inappropriate elimination fall into two general categories: 1) a dislike of the litter box, and 2) stress-related misbehavior. Why would a cat not like its litter box? One of the main reasons for this is because the litter box has become objectionable to the cat. This usually occurs because it is not cleaned frequently enough or because the cat does not like the litter in it. The latter is called substrate aversion; it can occur because the litter was changed to a new, objectionable type or because the cat just got tired of the old litter. What stresses can cause inappropriate elimination? There are probably hundreds of these, but the more common ones are as follows: a) A new person (especially a baby) in the house b) A person that has recently left the house (permanently or temporarily) c) New furniture d) New drapes e) New carpet f) Rearrangement of the furniture g) Moving to a new house h) A new pet in the house i) A pet that has recently left the house j) A new cat in the neighborhood that can be seen by the indoor cat k) A cat in “heat” in the neighborhood l) A new dog in the neighborhood that can be heard by the indoor cat I feel that this is a problem that cannot be tolerated, even if the cat has to leave my house.
    [Show full text]
  • Abnormal Noradrenergic Function in Posttraumatic Stress Disorder
    Original Article Abnormal Noradrenergic Function in Posttraumatic Stress Disorder Steven M. Southwick, MD; John H. Krystal, MD; C. Andrew Morgan, MD; David Johnson, PhD; Linda M. Nagy, MD; Andreas Nicolaou, PhD; George R. Heninger, MD; Dennis S. Charney, MD • To evaluate possible abnormal noradrenergic neuronal of stress. The effects of stress on brain noradrenergic func­ regulation in patients with posttraumatic stress disorder tion have been particularly well studied. For example, (PTSD), the behavioral, biochemical, and cardiovascular stress, especially uncontrollable stress, produces an ele­ effects of intravenous yohimbine hydrochloride (0.4 mg/kg) vated sense of fear and anxiety and causes regional were determined in 18 healthy male subjects and 20 male increases in norepinephrine turnover in the locus ceruleus patients with PTSD. A subgroup of patients with PTSD were (LC), limbic regions (hypothalamus, hippocampus, and observed to experience yohimbine-induced panic attacks amygdala), and cerebral cortex.3,4 In addition, a series of (70% [14/20]) and flashbacks (40% [8/20]), and they had investigations have shown that uncontrollable stress re­ larger yohimbine-induced increases in plasma 3-methoxy­ sults in an increased responsiveness of LC neurons to ex­ 4-hydroxyphenylglycol levels, sitting systolic blood pres­ citatory stimulation that is associated with a reduction in 5,6 sure, and heart rate than those in healthy subjects. In addi­ a2-adrenergic autoreceptor sensitivity. tion, in the patients with PTSD, yohimbine induced Recent clinical investigations suggest that a subgroup of significant increases in core PTSD symptoms, such as intru­ patients with chronic PTSD may exhibit abnormalities in sive traumatic thoughts, emotional numbing, and grief.
    [Show full text]
  • What Is a Panic Attack Disorder Within a Given Year
    11/6/2014 Top 3 Things You Should Know About Panic Attacks From: Tramaine Stevenson, Director of Program Development and Operations, National Council Date sent 11/05/2014 02:11:49 pm Subject: Top 3 Things You Should Know About Panic Attacks If you have difficulty viewing this message please click here. Interested in becoming a Mental Health First Aid instructor? Check out our Mental Health First Aider eNews recently announced National Council- hosted instructor trainings in California, In this week's issue, we discuss the top 3 things you should know South Carolina, Tennessee, New about panic attacks: what they are, what they look like, and how Mexico, and Texas. you can help using your Mental Health First Aid skills. More than 1 in 5 people will experience a panic attack in their lifetime. 2.7% of adults will develop a panic What is a Panic Attack disorder within a given year. A panic attack is a sudden onset of intense anxiety, fear, or terror that often occurs for no clear reason. Panic attacks can occur at any time—even in your sleep. Panic attacks peak around 10 minutes, but the physical symptoms can extend for a longer period of time. Panic disorder is when a person experiences recurring panic attacks and is persistently http://echo4.bluehornet.com/hostedemail/email.htm?CID=28367546178&ch=9E17608366076582BB3B29A03EE35827&h=cc4156c7bda4f2955eef9d28160531fa&… 1/4 11/6/2014 Top 3 Things You Should Know About Panic Attacks worried—for at least 1 month—about possible future panic attacks and the consequences of panic attacks. Some individuals with panic disorder go on to develop agoraphobia: avoiding places due to the fear of having a panic attack.
    [Show full text]
  • IBS Treatment
    TREATMENTS OF IBS Douglas A. Drossman, MD Co-Director UNC Center for Functional GI & Motility Disorders INTRODUCTION In recent years, there has been increased interest by physicians and the pharmaceutical industry regarding newer treatments for IBS. Before discussing these new treatments, it is important to consider the overall management strategy in IBS. This is necessary because patients with IBS exhibit a wide spectrum of symptoms of varying frequencies and degrees of severity. There is no one ideal treatment for IBS, and the newer medications may work best for only a subset of patients having this disorder. Therefore, the clinician must first apply certain general management approaches and, following this, treatment choices will depend on the nature (i.e., predominant diarrhea, constipation, or bloating, etc.) and severity (mild, moderate, severe) of the symptoms. The symptoms of IBS may have any of several underlying causes. These can include: (a) abnormal motility (uncoordinated or excessive contractions that can lead to diarrhea, constipation, bloating) (b) visceral hypersensitivity (lower pain threshold of the nerves that can produce abdominal discomfort or pain) resulting from the abnormal motility, stress or infection (c) dysfunction of the brain's ability to regulate these visceral (intestinal) activities. Treatments will vary depending on which of these possibilities are occurring. In general, milder symptoms relate primarily to abnormal motility, often in response to food, activity or stress, and/or visceral hypersensitivity. They are commonly treated symptomatically with pharmacological agents directed at the gut. However, more severe symptoms often relate to dysfunction of the brain-gut regulatory system with associated psychosocial effects, and psychological or behavioral treatments and antidepressants are frequently helpful.
    [Show full text]
  • Clinical Guideline Drug/Drug Class: Antipsychotics Prepared By
    MassHealth Drug Utilization Review Program Commonwealth Medicine University of Massachusetts Medical School P.O. Box 2586 Worcester MA, 01613-2586 Clinical Guideline Drug/Drug Class: Antipsychotics Prepared by: Drug Utilization Review Program Prepared for: MassHealth Pharmacy Program Purpose: The purpose of this guideline is to clarify the procedures for approving and denying prior authorization (PA) requests for: Polypharmacy with two or more antipsychotics for members ≥ 18 years old (including first- generation [typical] and second-generation [atypical]) for greater than 60 days (excluding clozapine and injectable formulations) Orally disintegrating dosage forms and Versacloz® (clozapine) oral suspension Medication exceeding defined quantity limits Fanapt® (iloperidone), Invega® (paliperidone), Latuda® (lurasidone), Rexulti® (brexpiprazole), Saphris® (asenapine), and Vraylar® (cariprazine) for members of all ages and all quantities Abilify® (aripiprazole) and Seroquel XR® (quetiapine extended-release) for members 18 years of age and older and all quantities Background: Since 2003, MassHealth has determined that oral second-generation (atypical) antipsychotics (with the exception of clozapine and injectables) would require prior authorization for polypharmacy, defined as two or more second-generation (atypical) antipsychotics for greater than 60 days. Clozapine is excluded from the polypharmacy requirement because the guidelines for the treatment of schizophrenia recognize that combinations including clozapine have been reported. 1 In 2016, the adult antipsychotic polypharmacy criteria was updated and the PA restriction was expanded to include first-generation (typical), and second-generation (atypical) antipsychotics, excluding clozapine and injectable formulations. Orally disintegrating tablets (ODT) of aripiprazole, clozapine, olanzapine and risperidone, as well as Versacloz® (clozapine) oral suspension also require PA since there are more cost-effective alternatives available.
    [Show full text]
  • EMDR Therapy Protocol for Panic Disorders with Or Without Agoraphobia 53
    PANIC DISORDER AND AGORAPHOBIA EMDR Therapy Protocol for Panic Disorders 2 With or Without Agoraphobia Ferdinand Horst and Ad de Jongh Introduction Panic disorder, as stated in the Diagnostic and Statistical Manual of Mental Disorders, fi fth edition (DSM-5; American Psychiatric Association, 2013) is characterized by recurrent and unexpected panic attacks and by hyperarousal symptoms like palpitations, pounding heart, chest pain, sweating, trembling, or shaking. These symptoms can be experienced as cata- strophic (“I am dying”) and mostly have a strong impact on daily life. When panic disorder is accompanied by severe avoidance of places or situations from which escape might be diffi cult or embarrassing, it is specifi ed as “panic disorder with agoraphobia” (American Psychiatric Association, 2013). EMDR Therapy and Panic Disorder With or Without Agoraphobia Despite the well-examined effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) Therapy in the treatment of posttraumatic stress disorder (PTSD), the applicability of EMDR Therapy for other anxiety disorders, like panic disorders with or without agora- phobia (PDA or Pathological Demand Avoidance), has hardly been examined (de Jongh & ten Broeke, 2009). From a theoretical perspective, there are several reasons why EMDR Therapy could be useful in the treatment of panic disorder: 1. The occurrence of panic attacks is likely to be totally unexpected; therefore, they are often experienced as distressing, causing a subjective response of fear or help- lessness. Accordingly, panic attacks can be viewed as life-threatening experiences (McNally & Lukach, 1992; van Hagenaars, van Minnen, & Hoogduin, 2009). 2. Panic memories in panic disorder resemble traumatic memories in PTSD in the sense that the person painfully reexperiences the traumatic incident in the form of recurrent and distressing recollections of the event, including intrusive images and fl ashbacks (van Hagenaars et al., 2009).
    [Show full text]
  • The Evaluation of Spells
    r e V i e W the evaluation of spells I.N. van Loon1*, J. Lamberts1, G.D. Valk2, A.F. Muller1 1Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands, 2Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands, *corresponding author: tel.: +31 (0)88- 25 05 901, e-mail: [email protected] a B s t r a C t the differential diagnosis of spells is broad and includes table 1. Differential diagnosis of episodic symptoms both innocent and life-threatening conditions with a endocrine pharmacological considerable overlap in clinical presentation. extensive Pheochromocytoma Abrupt withdrawal of adrener- diagnostic testing is often performed, without reaching a Thyreotoxicosis gic inhibitor final diagnosis, or resulting in false-positives. a thorough Hypogonadism (menopause) MAO inhibitor in combination Medullary thyroid carcinoma with specific food medical history, including family history and medication, Pancreatic islet cell tumours Sympathicomimetic and physical examination are required to obtain clues (e.g. insulinoma, VIPoma) Hallucinating drugs (cocaine, Gastroenteropancreatic LSD) about the cause of a spell. an overview of spells with their neuroendocrine Chlorpropamide-alcohol flush stereotypic phenotype in general internal medicine practice tumours (carcinoid syndrome) Vancomycin is presented in this article. Besides, a diagnostic approach Hypoglycaemia Calcium antagonist is proposed for the clinical evaluation of spells. Cardiovascular neurological Labile hypertension Autonomic neuropathy
    [Show full text]